Patent · US Active

Beta-lactamase inhibitors

US10065957B2 · kind B2 · utility

1Cited by

3References

18Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Anthony Casarez · Princeton, US
Markus Furegati · Allschwil, CH
Guido Koch · Karlsruhe, DE
Xiaodong Lin · Walnut Creek, US
Flavio Ossola · Liestal, CH
Folkert Reck · Walnut Creek, US
Robert Lowell Simmons · San Francisco, US
Qingming Zhu · Walnut Creek, US

Key dates

Filing date	Sep 28, 2017
Grant date	Sep 4, 2018
Priority date	—
Expiry date	Sep 28, 2037

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.